Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)

To identify genetic and biomarker factors which affect the expression of Parkinson's Disease.

Primary objective: To define the severity and rates of progression of clinical features of Parkinson's Disease.

Secondary objective: To relate clinical phenomenology of Parkinson's disease to genetic and biomarker changes.

A. Parkinson's Disease patients

Inclusion criteria

• Diagnosis of Parkinson's disease, based on UK Brain Bank criteria and made within the preceding 3 years ('recent onset cases') or diagnosed at under 50 years ('under 50 years cases')
• Age ≥18 to <90years
• Subject is able and willing to provided informed consent.

Exclusion criteria

• Patient has severe comorbid illness that would prevent full study participation
• Patient has features indicating another type of degenerative parkinsonism, e.g. progressive supranuclear palsy
• Drug-induced parkinsonism (Drug-unmasked PD is allowed)
• Symmetrical lower body parkinsonism attributable to significant cortical and/or subcortical cerebrovascular disease (patients with 'incidental' small vessel disease on brain imaging are allowed).
• Negative or normal functional imaging of the presynaptic dopamine system
• The presence of UK Brain Bank exclusion criteria will be recorded at baseline, allowing for the presence of 1 or 2 exclusion criteria (e.g. dopamine antagonist Drug used; more than one affected relative) (if justified e.g. by abnormal SPECT).

B. First degree relatives Inclusion criteria

• Age ≥18 to < 90years
• Resident in the United Kingdom and able to access one of the PRoBaND study centres.
• Subject is able and willing to provided informed consent.

Exclusion criteria

• Subject has severe comorbid illness that would prevent study participation
• Subject already has a diagnosis of Parkinson's disease